You will be able to attend and participate in the Annual Meeting online by visiting where you will be able to listen to the meeting live, submit questions, and vote. Stockholders, and taking into account recent federal, state and local guidance that has been issued, we have determined that the Annual Meeting will be held in a virtual meeting format only, via the internet, with no physical in-person meeting. In light of the COVID-19 pandemic, for the safety of all of our people, including our Therapeutics, Inc., a Delaware corporation, to be held on Friday, June 4, 2021 at 8:30 a.m. You are cordially invited to attend the 2021 Annual Meeting of Shareholders (the ∺nnual Meeting) of Silverback Previous filing by registration statement number, or the Form or Schedule and the date of its filing.įorm, Schedule or Registration Statement No.: Proposed maximum aggregate value of transaction:įee paid previously with preliminary materials.Ĭheck box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. The amount on which the filing fee is calculated and state how it was determined): Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth Title of each class of securities to which transaction applies: Payment of Filing Fee (Check the appropriate box):įee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (Name of Person(s) Filing Proxy Statement, if other than the Registrant) ![]() (Name of Registrant as Specified In Its Charter) Soliciting Material Pursuant to §240.14a-12 For more information please visit us at or contact your usual Swanson Reed representative.Proxy Statement Pursuant to Section 14(a) of theĬonfidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ![]() Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes. Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test. you don’t need to have a patent to qualify). Less pain means less hesitation means less lives lost.Īre you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. The design of this EpiPen alternative would remove the need for needles, making administration less painful in a moment of panic. If the spray is approved, the company aims to launch the product in 2023. Food and Drug Administration by the third quarter of this year. ARS, which raised $55 million in a Series D round of funding last spring, plans to submit its NDA (new drug application) for neffy to the U.S. Silverback made a name for themselves for their experimental solid tumor therapy following a public offering in late 2020. The deal is expected to close in the fourth quarter of this year, pending stockholder approval. Silverback equity holders will own about 37% of the new company, and ARS’s 63%. The combined company is expected to have $265 million in cash, cash equivalents and marketable securities upon closing, including $240 million in cash from Silverback. The spray, called neffy, is a potential easy-to-use alternative to the EpiPen. The newly combined company will focus their expertise on regulatory approval and commercialization of ARS’s epinephrine nasal spray for severe allergic reactions. Going forward, the combined company will be called ARS Pharmaceuticals. ARS Pharmaceuticals has announced a merger with Silverback Therapeutics.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |